Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: MTSS1

Gene summary for MTSS1

Gene summary.

Gene information	Species	Human
	Gene symbol	MTSS1
	Gene ID	9788
	Gene name	MTSS I-BAR domain containing 1
	Gene Alias	MIM
	Cytomap	8q24.13
	Gene Type	protein-coding
	GO ID	GO:0001655
	UniProtAcc	O43312

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
9788	MTSS1	RNA-P7T1-P7T1-2	Human	Lung	AIS	2.90e-03	4.59e-01	-0.0876
9788	MTSS1	RNA-P7T1-P7T1-4	Human	Lung	AIS	4.60e-04	4.45e-01	-0.0809
9788	MTSS1	C04	Human	Oral cavity	OSCC	2.46e-23	1.15e+00	0.2633
9788	MTSS1	C21	Human	Oral cavity	OSCC	4.46e-65	1.90e+00	0.2678
9788	MTSS1	C30	Human	Oral cavity	OSCC	5.42e-34	1.68e+00	0.3055
9788	MTSS1	C38	Human	Oral cavity	OSCC	8.60e-12	1.12e+00	0.172
9788	MTSS1	C43	Human	Oral cavity	OSCC	1.35e-25	6.79e-01	0.1704
9788	MTSS1	C46	Human	Oral cavity	OSCC	1.32e-30	7.02e-01	0.1673
9788	MTSS1	C51	Human	Oral cavity	OSCC	1.27e-31	1.15e+00	0.2674
9788	MTSS1	C57	Human	Oral cavity	OSCC	3.49e-05	2.26e-01	0.1679
9788	MTSS1	C07	Human	Oral cavity	OSCC	1.70e-05	9.47e-01	0.2491
9788	MTSS1	C08	Human	Oral cavity	OSCC	1.43e-35	9.68e-01	0.1919
9788	MTSS1	LN22	Human	Oral cavity	OSCC	1.16e-04	7.21e-01	0.1733
9788	MTSS1	LN38	Human	Oral cavity	OSCC	1.97e-08	8.14e-01	0.168
9788	MTSS1	LN46	Human	Oral cavity	OSCC	1.01e-10	4.03e-01	0.1666
9788	MTSS1	LP15	Human	Oral cavity	LP	4.86e-03	7.69e-01	0.2174
9788	MTSS1	SYSMH1	Human	Oral cavity	OSCC	8.87e-51	1.10e+00	0.1127
9788	MTSS1	SYSMH2	Human	Oral cavity	OSCC	2.20e-09	4.89e-01	0.2326
9788	MTSS1	SYSMH3	Human	Oral cavity	OSCC	4.36e-33	9.41e-01	0.2442
9788	MTSS1	SYSMH5	Human	Oral cavity	OSCC	4.92e-28	7.30e-01	0.0647

Page: 1 2 3 4 5 6 7 8 9 10

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Cervix		CC: Cervix cancer
		HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions
		N_HPV: HPV-infected normal cervix
Colorectum (GSE201348)		FAP: Familial adenomatous polyposis
		CRC: Colorectal cancer
Colorectum (HTA11)		AD: Adenomas
		SER: Sessile serrated lesions
		MSI-H: Microsatellite-high colorectal cancer
		MSS: Microsatellite stable colorectal cancer
Endometrium		AEH: Atypical endometrial hyperplasia
		EEC: Endometrioid Cancer
Esophagus		ESCC: Esophageal squamous cell carcinoma
		HGIN: High-grade intraepithelial neoplasias
		LGIN: Low-grade intraepithelial neoplasias
Liver		HCC: Hepatocellular carcinoma
		NAFLD: Non-alcoholic fatty liver disease
Lung		AAH: Atypical adenomatous hyperplasia
		AIS: Adenocarcinoma in situ
		IAC: Invasive lung adenocarcinoma
		MIA: Minimally invasive adenocarcinoma
Oral Cavity		EOLP: Erosive Oral lichen planus
		LP: leukoplakia
		NEOLP: Non-erosive oral lichen planus
		OSCC: Oral squamous cell carcinoma
Prostate		BPH: Benign Prostatic Hyperplasia
Skin		AK: Actinic keratosis
		cSCC: Cutaneous squamous cell carcinoma
		SCCIS:squamous cell carcinoma in situ
Thyroid		ATC: Anaplastic thyroid cancer
		HT: Hashimoto's thyroiditis
		PTC: Papillary thyroid cancer

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:000701510	Cervix	CC	actin filament organization	109/2311	442/18723	4.92e-13	2.45e-10	109
GO:003297010	Cervix	CC	regulation of actin filament-based process	96/2311	397/18723	4.00e-11	8.54e-09	96
GO:190290310	Cervix	CC	regulation of supramolecular fiber organization	92/2311	383/18723	1.49e-10	2.48e-08	92
GO:003295610	Cervix	CC	regulation of actin cytoskeleton organization	86/2311	358/18723	5.90e-10	7.51e-08	86
GO:00506737	Cervix	CC	epithelial cell proliferation	98/2311	437/18723	2.01e-09	2.15e-07	98
GO:00452169	Cervix	CC	cell-cell junction organization	53/2311	200/18723	3.83e-08	2.53e-06	53
GO:011005310	Cervix	CC	regulation of actin filament organization	67/2311	278/18723	4.01e-08	2.54e-06	67
GO:00506787	Cervix	CC	regulation of epithelial cell proliferation	83/2311	381/18723	1.31e-07	6.42e-06	83
GO:006157210	Cervix	CC	actin filament bundle organization	44/2311	161/18723	2.08e-07	9.34e-06	44
GO:005101710	Cervix	CC	actin filament bundle assembly	43/2311	157/18723	2.66e-07	1.12e-05	43
GO:190290510	Cervix	CC	positive regulation of supramolecular fiber organization	50/2311	209/18723	2.55e-06	7.54e-05	50
GO:005149510	Cervix	CC	positive regulation of cytoskeleton organization	50/2311	226/18723	2.53e-05	4.29e-04	50
GO:003223110	Cervix	CC	regulation of actin filament bundle assembly	28/2311	105/18723	5.19e-05	7.79e-04	28
GO:00322339	Cervix	CC	positive regulation of actin filament bundle assembly	18/2311	63/18723	4.39e-04	4.39e-03	18
GO:00605626	Cervix	CC	epithelial tube morphogenesis	57/2311	325/18723	3.79e-03	2.41e-02	57
GO:00343326	Cervix	CC	adherens junction organization	13/2311	49/18723	5.34e-03	3.10e-02	13
GO:00070092	Cervix	CC	plasma membrane organization	28/2311	142/18723	7.85e-03	4.14e-02	28
GO:00343316	Cervix	CC	cell junction maintenance	10/2311	35/18723	7.99e-03	4.18e-02	10
GO:00344051	Cervix	CC	response to fluid shear stress	10/2311	35/18723	7.99e-03	4.18e-02	10
GO:00714983	Cervix	CC	cellular response to fluid shear stress	7/2311	21/18723	1.04e-02	4.97e-02	7

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24

Enriched KEGG pathways.

Pathway ID

Tissue

Disease Stage

Description

Gene Ratio

Bg Ratio

pvalue

p.adjust

qvalue

Count

Page: 1

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

MTSS1

SNV

Missense_Mutation

c.923C>G

p.Ser308Cys

p.S308C

O43312

protein_coding

tolerated(0.11)

probably_damaging(1)

TCGA-A2-A0YH-01

Breast

breast invasive carcinoma

Female

<65

III/IV

Chemotherapy

adriamycin

MTSS1

SNV

Missense_Mutation

c.294C>A

p.Ser98Arg

p.S98R

O43312

protein_coding

tolerated(0.06)

probably_damaging(0.988)

TCGA-A8-A07R-01

Breast

breast invasive carcinoma

Female

>=65

III/IV

Ancillary

zoledronic

MTSS1

SNV

Missense_Mutation

c.1084N>A

p.Glu362Lys

p.E362K

O43312

protein_coding

tolerated(0.46)

benign(0.182)

TCGA-AC-A23H-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

MTSS1

SNV

Missense_Mutation

rs762528178

c.1930N>T

p.Arg644Trp

p.R644W

O43312

protein_coding

tolerated(0.18)

possibly_damaging(0.84)

TCGA-AR-A1AK-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Hormone Therapy

anastrozole

MTSS1

SNV

Missense_Mutation

c.252G>A

p.Met84Ile

p.M84I

O43312

protein_coding

deleterious(0.03)

probably_damaging(0.993)

TCGA-AR-A250-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

doxorubicin

MTSS1

SNV

Missense_Mutation

novel

c.1532N>T

p.Thr511Ile

p.T511I

O43312

protein_coding

deleterious(0)

probably_damaging(1)

TCGA-BH-A0HF-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Hormone Therapy

arimidex

MTSS1

SNV

Missense_Mutation

novel

c.1268N>C

p.Asp423Ala

p.D423A

O43312

protein_coding

deleterious(0)

probably_damaging(1)

TCGA-BH-A204-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

MTSS1

SNV

Missense_Mutation

rs149780096

c.1395N>A

p.Met465Ile

p.M465I

O43312

protein_coding

tolerated(0.46)

benign(0.023)

TCGA-C8-A12T-01

Breast

breast invasive carcinoma

Female

<65

I/II

Unknown

MTSS1

SNV

Missense_Mutation

novel

c.421N>G

p.Ser141Ala

p.S141A

O43312

protein_coding

deleterious(0.01)

probably_damaging(0.998)

TCGA-S3-AA11-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Hormone Therapy

letrozole

MTSS1

insertion

Nonsense_Mutation

novel

c.1292_1293insAAAAAATAATAATAAATAAA

p.Arg432LysfsTer6

p.R432Kfs*6

O43312

protein_coding

TCGA-A7-A0CJ-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

cytoxan

Page: 1 2 3 4 5 6 7 8 9 10

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID

Symbol

Category

Interaction Types

Drug Claim Name

Drug Name

PMIDs

Page: 1